Cytomx therapeutics, inc. (CTMX)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Cash flows from operating activities:
Net income (loss)

12,205

-35,456

-23,697

-28,961

-14,124

-32,233

-23,431

-13,447

-15,493

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-10,247

-25,216

-8,257

-14,033

-14,662

-14,176

-16,029

-11,487

-11,870

-5,806

-6,211

Adjustments to reconcile net income (loss) to net cash used in operating activities:
Loss/(gain) on disposal of property and equipment

-

-

-

-

-

-

-

-

-

-

0

0

1

-

-

-

-

-

-

-

-

Amortization of intangible assets

36

37

36

37

36

37

36

37

36

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation and amortization

601

-

-

-

617

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation and amortization

-

-

-

-

-

-

-

426

376

-

477

369

395

490

443

445

355

329

307

302

268

Amortization of debt discount

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

57

10

13

Accretion of discounts on investments

127

265

556

694

713

587

471

382

261

21

-55

-134

-203

-406

-439

-467

-350

-370

-381

-311

-124

Stock-based compensation expense

4,013

4,111

4,343

5,454

5,192

4,616

4,413

4,161

3,688

2,750

2,780

3,010

2,747

2,622

2,720

2,391

2,362

1,921

1,344

546

175

Issuance of common stock in connection with UCSB sublicense fee

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

159

-

-

-

-

Deferred income taxes

-

-

-

-

-

-

-

-

-

-520

-19

25

1

0

0

3

3

-

-

-

-

Changes in operating assets and liabilities
Accounts receivable

129,997

6

-9,997

9,960

-53

41

-25,081

25,056

-10,058

9,956

25

-55

-1,946

1,919

-45

-31

-56

-1,204

-141

216

-2

Related party accounts receivable

-

-

-

-

-

-

-

-

-

-68

41

-28

-99

-53

94

-45

-214

-

-84

205

-1,663

Prepaid expenses and other current assets

14,957

-1,881

1,527

-906

-814

1,361

1,660

756

1,122

-496

269

461

222

-505

990

-27

1,139

1,095

-283

269

410

Other assets

-636

-

-

-

-

0

0

0

20

-1,716

-169

487

-220

2,747

-42

-41

-55

-7

-71

-28

-22

Accounts payable

52

-526

149

-5,159

5,162

-2,534

3,224

-1,544

1,115

1,054

-3,574

2,904

-2,825

5,824

-853

-3,452

246

2,195

1,599

-283

-567

Accrued liabilities, income tax payable and other long-term liabilities

-2,615

9,380

-2,000

-13,499

-6,605

14,281

-751

10,158

1,145

5,033

4,357

1,576

-1,809

-

-

-

-

-

-

-

-

Accrued liabilities and other liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-134

1,762

2,696

-371

-

-

-

-

Deferred revenue

80,416

-8,566

-10,705

991

-29,461

-11,382

-12,466

-213

-14,134

-

-

-

-

-

-

-

-

-

-

-

-

Accrued liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-169

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-10,101

191,258

-11,583

-

-3,034

27,236

8,199

-1,533

-1,532

-1,533

-1,532

Net cash used in operating activities

-49,737

-29,479

-23,319

-48,653

-39,029

-28,742

-5,551

-26,616

-14,612

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from investing activities:
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-19,086

-

-14,182

15,754

-5,540

-8,169

-7,766

-6,111

-5,369

Purchases of property and equipment

1,049

703

628

331

1,835

1,119

1,050

868

751

234

57

324

944

602

863

384

327

182

363

794

255

Purchases of short-term investments

44,707

25,460

47,889

39,326

62,317

42,858

62,113

51,498

48,132

-

-

-

-

-

-

-

-

-

-

-

-

Maturities of short-term investments

48,197

79,020

87,027

46,597

45,546

59,819

59,983

69,013

25,500

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of short-term investments

-

-

-

-

-

-

-

-

-

-

0

14,089

40,094

-

23,577

64,096

33,844

121,348

39,590

38,175

51,788

Maturities of short-term investments

-

-

-

-

-

-

-

-

-

-

16,000

27,750

40,250

-

35,750

43,000

47,750

-

-

-

-

Net cash provided by (used in) investing activities

2,441

52,857

38,510

6,940

-18,606

15,842

-3,180

16,647

-23,383

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from financing activities:
Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-250

73,489

1,191

Net cash used in investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-788

-

11,310

-21,480

13,579

-50,847

1,297

-28,969

-52,043

Proceeds from employee stock purchase plan and exercise of stock options

2,157

401

63

698

465

724

980

722

2,602

1,122

1,160

666

891

501

251

130

48

-

-

-

-

Repayment of notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-6,094

2,309

362

356

Payment of deferred offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

12

-

-

-

-

Net cash provided by financing activities

2,157

401

63

698

465

724

135,576

722

2,602

-

-

-

-

-

-

-

-

-

-

-

-

Net decrease in cash, cash equivalents and restricted cash

-45,139

23,779

15,254

-41,015

-57,170

-12,176

126,845

-9,247

-35,393

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

891

-

251

208

36

82,647

-3,182

73,103

835

Net increase in cash, cash equivalents and restricted cash

-

-

-

-

-

-

-

-

-

-

11,365

187,198

-18,983

-

-2,621

-5,518

8,075

23,631

-9,651

38,023

-56,577

Supplemental disclosures of cash flow information:
Cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

61

75

84

Supplemental disclosures of noncash investing and financing items:
Purchases of property and equipment in accounts payable and accrued liabilities

-

135

-119

167

245

794

-593

435

391

-

-

-

230

415

-88

120

26

-14

44

-393

463

Right of use assets obtained in exchange for operating lease obligations

-

-

-

-

28,054

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accretion to redemption value and cumulative dividends on preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

558

2,958

1,757

1,432